Best in Biotech 14 Dec 2023
Seven companies shaping the future of precision medicine
Explore the forefront of healthcare innovation with these seven cutting-edge biopharma companies specializing in precision medicine.
Metabolic disorders
- Latest Posts
8 life science innovators you must meet at BioTrinity 2023
News and Trends 24 Feb 2023
Resalis Therapeutics receives €10M to develop obesity and NAFLD treatment
Resalis Therapeutics has completed a seed financing round of €10 million to establish a non-coding RNA (ncRNA)-based therapeutic approach for the treatment of metabolic diseases. The funding will support the finalization of IND-enabling studies for the Resalis Therapeutics’ lead program, RES-010, which Resalis will initially develop as a novel treatment for obesity and nonalcoholic fatty […]
News and Trends 16 Dec 2022
Sosei Heptares and Lilly enter agreement on diabetes and metabolic diseases
Sosei Group Corporation has entered a drug discovery collaboration with Eli Lilly and Company to discover, develop and commercialize small molecules that modulate novel G protein-coupled receptor (GPCR) targets associated with diabetes and metabolic diseases. The agreement will leverage Sosei Heptares’ StaR technology and structure-based drug design (SBDD) platform and Lilly’s drug development and commercialization […]
News and Trends 11 Aug 2022
Study of drug to treat porphyria disorders initiated by Disc Medicine
A phase 2 clinical study of bitopertin in patients with erythropoietic protoporphyria (EPP) or X-linked protoporphyria (XLP) has been initiated by Disc Medicine. The announcement of the study, called BEACON, was made August 10. EPP or XLP belong to a group of the porphyria disorders, which are all characterized by abnormally high levels of chemicals, […]
Opinion 11 Jul 2022
Precision medicine: the next big leap for metabolic disorders
Chronic metabolic disorders like type 2 diabetes and cardiovascular disease are a huge burden on healthcare systems, and their treatment is often fragmented and reliant on trial-and-error approaches. Rebecca Cripps and Robert Thong at MultiOmic Health explain how precision medicine is set to change the way we think about these disorders. Metabolic disorders constitute the […]
ADVERTISEMENT
ADVERTISEMENT
News and Trends 5 Jul 2022
Poxel publishes ALD studies
Two preclinical articles have been published in different journals for treatments being developed by French biopharmaceutical company, Poxel. Poxel develops treatments for chronic, serious diseases with metabolic pathophysiology including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders. The articles have been about genetic disease X-Linked Adrenoleukodystrophy (ALD) and molecules PXL065 and PXL770. These molecules have separate […]
ADVERTISEMENT